An ambitious company that has quickly become one of the world’s leading developers of biosimilar drugs, is to start developing novel biologics after announcing a collaboration with Japan’s largest drugmaker.
Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB) that was only formally founded in 2012, is already bringing its pipeline of biosimilars of some of the world’s best-selling rheumatology and oncology drugs to fruition in major markets.
"Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze